The DOI matches its Crossref record.
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Open accessAbstract
BACKGROUND: Despite complete resection, disease-free survival (DFS) of patients with cholangiocarcinoma (CCA) is less than 65 % after one year and not more than 35 % after three years. For muscle invasive gallbladder carcinoma (GBCA), prognosis is even worse, with an overall survival (OS) of only 30 % after three years. Thus, evaluation of adjuvant chemotherapy in biliary tract cancer in a large randomized trial is warranted. METHODS/DESIGN: ACTICCA-1 is a randomized, multidisciplinary, multinational phase III investigator initiated trial. With respect to data obtained in the ABC-02 trial, we selected the combination of gemcitabine and cisplatin for 24 weeks as investigational treatment. Based on adjuvant trials in pancreatic cancer with comparable postoperative recovery time, inclusion of patients within a maximum interval of 16 weeks between surgery and start of chemotherapy was stipulated. Due to the different prognosis and treatment susceptibility of muscle invasive carcinoma, two separate cohorts (CCA and GBCA) were included to capture the potentially different treatment effects. Randomization is stratified for lymph node status for both cohorts and localization for CCA. The primary endpoint is DFS and secondary endpoints include OS, safety and tolerability of chemotherapy, quality of life, and patterns of disease recurrence. For CCA, adjuvant chemotherapy should increase DFS 24 months post-surgery from 40 to 55 % to be considered relevant. With a power of 80 % and a significance level of 5 %, 271 evaluable study patients have to be followed for 24-28 months to observe 166 events. For GBCA, chemotherapy should increase DFS 24 months post-surgery from 35 to 55 % to be of relevance; thus, 154 evaluable study patients have to be monitored for 24-28 months to observe 90 events. In both cohorts, randomization will be 1:1 with chemotherapy for 24 weeks and imaging every twelve weeks. In 2014, the study was initiated in Germany and in The Netherlands (funded by the Deutsche Krebshilfe, the Dutch Cancer Society, and supported by medac GmbH). Sites in Australia, Denmark, and the United Kingdom (funded by Cancer Research UK) are joining 2015. TRIAL REGISTRATION: The study is registered with ClinicalTrials.gov ( NCT02170090 ) and the European Clinical Trials Database (2012-005078-70). Registration date is 06/18/2014.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Self-citationValle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Moris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21759 · Cited by 451
Roa, J. C., García, P., Kapoor, V. K., Maithel, S. K., Javle, M., & Koshiol, J. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00398-y · Cited by 401
Ebata, T., Hirano, S., Konishi, M., Uesaka, K., Tsuchiya, Y., Ohtsuka, M., Kaneoka, Y., Yamamoto, M., Ambo, Y., Shimizu, Y., et al. (2018) · British Journal of Surgery · doi:10.1002/bjs.10776 · Cited by 397
Metadata
- Authors
- Stein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L. H., Klümpen, H.-J., Lohse, A. W., Nashan, B., Primrose, J., Schrum, S., Shannon, J., Vettorazzi, E., & Wege, H.
- Venue
- BMC Cancer
- Published
- 2015-07-31
- Volume
- 15
- Issue
- 1
- Pages
- 564-564
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W1486884945
- Cited by
- 238
- References
- 0
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. https://app.cochat.ai/papers/10.1186/s12885-015-1498-0
- The paper
- Stein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L. H., Klümpen, H.-J., Lohse, A. W., Nashan, B., Primrose, J., Schrum, S., Shannon, J., Vettorazzi, E., & Wege, H. (2015). Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. https://doi.org/10.1186/s12885-015-1498-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.